Clinical Trial Update: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy [Phase 2]

View source ↗

Summary

Phase 2 randomized trial of ABT-494 in moderately to severely active Crohn's disease completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• ABT-494 (upadacitinib)

Snippet

Sponsor: AbbVie | Conditions: Crohn's Disease | Phase 2 | Status: COMPLETED | Results posted: 2023-08-14